Rankings / Immune & Inflammation
Larazotide acetate (AT-1001)
Immune & Inflammation · Tight junction regulator
Tier D+
Bottom line
Read Off Label grades Larazotide acetate (AT-1001) as D+ (3.4/10) based on weak evidence, weak benefit magnitude, and a unclear-risk safety profile.
Failed Ph3 primary endpoint in celiac disease 2022 despite promising Ph2b.
Studied, labeled, or reported-use context: 0. — Not FDA-approved; 9 Meters discontinued development; gray-market research peptide; not individualized guidance.
What the evidence says
Failed Ph3 primary endpoint in celiac disease 2022 despite promising Ph2b. Some use in 'leaky gut' biohacker protocols despite the failed trial. Mechanism is legitimate but real-world benefit unproven.
Mechanism
Octapeptide zonulin antagonist; tightens intestinal tight junctions; reduces intestinal permeability; developed for celiac disease adjunct to GFD
Studied, labeled, or reported dose & route
0.5 mg PO 3x/day in trials
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Larazotide acetate (AT-1001)'s effects?
- Read Off Label rates the evidence for Larazotide acetate (AT-1001) as Weak and the benefit magnitude as weak, producing an overall grade of D+ (3.4/10). Failed Ph3 primary endpoint in celiac disease 2022 despite promising Ph2b.
- What safety findings are reported for Larazotide acetate (AT-1001)?
- Larazotide acetate (AT-1001) has a unclear risk profile in the database. Unknown (favorable in trials but Ph3 negative) Legal status: Not FDA-approved; 9 Meters discontinued development; gray-market research peptide.
- What doses or routes are reported for Larazotide acetate (AT-1001)?
- 0.5 mg PO 3x/day in trials This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Larazotide acetate (AT-1001) work?
- Octapeptide zonulin antagonist; tightens intestinal tight junctions; reduces intestinal permeability; developed for celiac disease adjunct to GFD
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.